

11 September 2008

Dr Carole Longson
Director
Health Technology Evaluation Centre
National Institute for Health and Clinical Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 6NA



*Quarry House
Quarry Hill
Leeds
LS2 7UE*

Tel: 0113 254 5000

Dear Carole

Single Technology Appraisal – Lapatinib (Tyverb) for late stage breast cancer

I am writing with regard to the Department of Health's position on GSK's proposed scheme for Lapatinib. Through this scheme, the company would pay for up to the first 12 weeks of the treatment for each patient initiated on Lapatinib. The NHS will bear the cost of continued treatment with Lapatinib for any patients beyond week 12.

This proposal appears relatively simple to administer and is consistent with NHS Financial flows. It is fully transparent and we have no objections from a clinical standpoint. Therefore, I can confirm that the Department of Health is content for NICE to incorporate the proposed scheme into its appraisal.

Yours sincerely

A black rectangular box redacting the signature of the sender.

A black rectangular box redacting the name of the sender.

Medicines, Pharmacy and Industry Group